cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by genzyme corporation. it is given intravenously after reconstitution as a treatment for type 1 and type 3 gaucher's disease. it is available in formulations containing 200 or 400 units per vial. the specific activity of highly purified human enzyme is 890,000 units/mg. a typical dose is 2.5u/kg every two weeks, up to a maximum of 60 u/kg once every two weeks, and safety has been established from ages 2 and up. it is one of more expensive medications, with an annual cost of $200,000 per person in the united states. imiglucerase has been granted orphan drug status in the united states, australia, and japan.